Helixmith Co. Ltd

Helixmith Co., Ltd is a biotechnology company that discovers and develops biopharmaceuticals for human diseases. Its pipeline includes novel biologics and herbal therapeutics in cardiovascular disease, cancer, and immune disorders, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. Other pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu-positive breast or ovarian cancer, and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. It was incorporated in 1996 and is headquartered in Seoul, South Korea.